World Journal of Endocrine Surgery

Register      Login

VOLUME 12 , ISSUE 1 ( January-April, 2020 ) > List of Articles

Original Article

Rising Incidence of Neuroendocrine Tumors in Singapore: An Epidemiological Study

Prajwala S Prakash, Sujith Wijerathne

Citation Information : Prakash PS, Wijerathne S. Rising Incidence of Neuroendocrine Tumors in Singapore: An Epidemiological Study. World J Endoc Surg 2020; 12 (1):1-4.

DOI: 10.5005/jp-journals-10002-1280

License: CC BY-NC 4.0

Published Online: 30-10-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Aim: The incidence of neuroendocrine tumors (NETs) is increasing worldwide. This study presents the epidemiological trends of NETs and survival results from Singapore. Materials and methods: This is a retrospective population-based study of all NETs treated during 1993–2014 in Singapore. The primary outcome studied was trends in incidence of NETs, and secondary outcomes were gender, ethnic and histological variations, and overall survival results. Results: During the study period, 1,725 cases were identified and the age-standardized incidence increased from 0.8 to 3 per 100,000 per year. The mean age of diagnosis was 56.0 (±25.5) years, with the highest incidence among ethnic Chinese (n = 1391, 80.6%) and gender ratio nearly 1:1. Histologically, the tumors were predominantly carcinoid tumor (52.6%) and neuroendocrine carcinoma (40.3%), with tumors arising most commonly in the rectum (26.0%), colon (13.7%), lung and bronchus (13.7%), pancreas (9.4%), stomach (7.1%), small intestine (5.9%), and other organs (24.1%). Majority were G1 (51.9%) and G3 (33.9%) tumors, and of clinical stage I (41.0%) and stage IV (35.9%). The most commonly rendered treatment was surgery alone (36.2%). The 5-year overall survival for the cohort for all NETs was 38.1%, and 10-year survival was 22.0%. Predictors for poor survival in this cohort include primary tumor site, gender, and advancing age. Conclusion and clinical significance: The incidence of NETs in Singapore has markedly increased nearly fourfold over the last two decades, possibly due to improved detection. However, there are various other unevaluated factors that warrant further investigation.

  1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3(10):1335–1342. DOI: 10.1001/jamaoncol.2017.0589.
  2. Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015;121(4):589–597. DOI: 10.1002/cncr.29099.
  3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934–959. DOI: 10.1002/cncr.11105.
  4. Fraenkel M, Kim M, Faggiano A, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer 2014;21(3):R153–R163. DOI: 10.1530/ERC-13-0125.
  5. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010;105(12):2563–2569. DOI: 10.1038/ajg.2010.341.
  6. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for Neuroendocrine tumors in 35,825 cases in the United states. J Clin Oncol 2008;26(18): 3063–3072. DOI: 10.1200/JCO.2007.15.4377.
  7. Skuladottir H, Hirsch FR, Hansen HH, et al. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. a population-based study in Denmark. Lung Cancer 2002;37(2):127–135. DOI: 10.1016/S0169-5002(02)00080-6.
  8. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and north America. Cancer 2008;113(10):2655–2664. DOI: 10.1002/cncr.23883.
  9. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92(8): 2204–2210. DOI: 10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R.
  10. Korse CM, Taal BG, van Velthuysen ML, et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 2013;49(8):1975–1983. DOI: 10.1016/j.ejca.2012.12.022.
  11. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine tumour society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17(4):909–918. DOI: 10.1677/ERC-10-0152.
  12. Ito T, Tanaka M, Imamura M. Neuroendocrine tumor workshop J. [results of a nationwide survey of gastrointestinal tumors in Japan]. Nihon Geka Gakkai Zasshi 2008;109(3):128–132.
  13. Ito T, Tanaka M, Sasano H, et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007;42(6):497–500. DOI: 10.1007/s00535-007-2056-6.
  14. Tsai HJ, Wu CC, Tsai CR, et al. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One 2013;8(4):e62487. DOI: 10.1371/journal.pone.0062487.
  15. Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol 2012;19(9):2932–2936. DOI: 10.1245/s10434-012-2285-7.
  16. Modlin IM, Moss SF, Chung DC, et al. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008;100(18):1282–1289. DOI: 10.1093/jnci/djn275.
  17. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. 4th edn, Lyon, France: International Agency for Research on Cancer (IARC); 2010.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.